Tranexamic acid is a synthetic amino acid antifibrinolytic drug, which can competitively inhibit the combination of lysine and plasmin of fibrin, so as to inhibit the cracking of fibrin clot and produce hemostasis. It is mainly used in various bleeding caused by hyperfibrinolysis in clinic. Tranexamic acid is a synthetic lysine analogue, which can competitively bind to the lysine binding site on plasminogen and plasmin, so as to competitively inhibit the degradation of fibrin, reduce fibrinolytic activity and play a role in promoting coagulation. Theoretically, the use of tranexamic acid can lead to insufficient fibrinolytic activity, so it may increase the risk of postoperative thrombotic events.
Manufacturing
